Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Signal discloses a novel group of JNK inhibitors for a wide range of conditions

March 15, 2002

SLIL claims potential new treatments for prostate cancer

March 14, 2002

Derivatives with antitumor activity identified at Zentaris

March 14, 2002

FDA issues complete review letter for Bexxar, requests further clinical studies

March 14, 2002

Genmab and Bionomics collaborate on human antibody development for angiogenesis targets

March 14, 2002

Ricerca inlicenses RAP-3 gene for oncology drug discovery

March 14, 2002

Zevalin advances to clinical trials in Japan

March 14, 2002

SRF2, a TGF-beta antagonist, available for licensing from NIH

March 14, 2002

Atrix licenses Israeli Eligard marketing rights to Luxembourg

March 13, 2002

Promising preclinical results for Celgene's JNK inhibitors

March 13, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.